Magrolimab, a monoclonal antibody targeting CD47, an interesting signaling pathway which is interpreted as “Don’t eat me” by tumor-infiltrating macrophages, has showed potential activity for effectively treating TP53-mutated AML. Here, CD47 is linked to acute myeloid leukemia.